| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Cannabidiol (Epidiolex) for epilepsy. The Medical letter on drugs and therapeutics. vol 60. issue 1559. 2019-02-04. PMID:30681657. |
cannabidiol (epidiolex) for epilepsy. |
2019-02-04 |
2023-08-13 |
Not clear |
| Jesse Elliott, Deirdre DeJean, Tammy Clifford, Doug Coyle, Beth Potter, Becky Skidmore, Christine Alexander, Alexander E Repetski, Bláthnaid McCoy, George A Well. Cannabis for pediatric epilepsy: protocol for a living systematic review. Systematic reviews. vol 7. issue 1. 2019-01-07. PMID:30021618. |
cannabis for pediatric epilepsy: protocol for a living systematic review. |
2019-01-07 |
2023-08-13 |
Not clear |
| María Rodríguez-Muñoz, Yara Onetti, Elsa Cortés-Montero, Javier Garzón, Pilar Sánchez-Blázque. Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor. Molecular brain. vol 11. issue 1. 2019-01-07. PMID:30223868. |
cannabidiol (cbd), the major non-psychotomimetic compound present in the cannabis sativa plant, exhibits therapeutic potential for various human diseases, including chronic neurodegenerative diseases, such as alzheimer's and parkinson's, ischemic stroke, epilepsy and other convulsive syndromes, neuropsychiatric disorders, neuropathic allodynia and certain types of cancer. |
2019-01-07 |
2023-08-13 |
human |
| Arti Kerai, Tin Fei Sim, Lynne Emmerto. Medical cannabis: A needs analysis for people with epilepsy. Complementary therapies in clinical practice. vol 33. 2018-12-19. PMID:30396625. |
medical cannabis: a needs analysis for people with epilepsy. |
2018-12-19 |
2023-08-13 |
Not clear |
| Arti Kerai, Tin Fei Sim, Lynne Emmerto. Medical cannabis: A needs analysis for people with epilepsy. Complementary therapies in clinical practice. vol 33. 2018-12-19. PMID:30396625. |
medical cannabis may be effective treatment for refractory epilepsy. |
2018-12-19 |
2023-08-13 |
Not clear |
| William O Pickrell, Neil P Robertso. Cannabidiol as a treatment for epilepsy. Journal of neurology. vol 264. issue 12. 2018-12-13. PMID:29124331. |
cannabidiol as a treatment for epilepsy. |
2018-12-13 |
2023-08-13 |
Not clear |
| Rhys H Thomas, Mark O Cunningha. Cannabis and epilepsy. Practical neurology. vol 18. issue 6. 2018-12-11. PMID:30337476. |
cannabis and epilepsy. |
2018-12-11 |
2023-08-13 |
Not clear |
| Moran Hausman-Kedem, Shay Menascu, Uri Krame. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study. Brain & development. vol 40. issue 7. 2018-10-22. PMID:29674131. |
efficacy of cbd-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - an observational, longitudinal study. |
2018-10-22 |
2023-08-13 |
Not clear |
| Moran Hausman-Kedem, Shay Menascu, Uri Krame. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study. Brain & development. vol 40. issue 7. 2018-10-22. PMID:29674131. |
the objective of this observational study was to evaluate the efficacy of medical cannabis for the treatment of refractory epilepsy. |
2018-10-22 |
2023-08-13 |
Not clear |
| Moran Hausman-Kedem, Shay Menascu, Uri Krame. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study. Brain & development. vol 40. issue 7. 2018-10-22. PMID:29674131. |
fifty-seven patients (age 1-20 years) with epilepsy of various etiologies were treated with cannabis oil extract (cbd/thc ratio of 20:1) for at least 3 months (median follow up time-18 months). |
2018-10-22 |
2023-08-13 |
Not clear |
| Moran Hausman-Kedem, Shay Menascu, Uri Krame. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study. Brain & development. vol 40. issue 7. 2018-10-22. PMID:29674131. |
there was no statistically significant difference in response rate among various epilepsy etiologies, and cannabis strain used. |
2018-10-22 |
2023-08-13 |
Not clear |
| Moran Hausman-Kedem, Shay Menascu, Uri Krame. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study. Brain & development. vol 40. issue 7. 2018-10-22. PMID:29674131. |
our results suggest that adding cbd-enriched cannabis extract to the treatment regimen of patients with refractory epilepsy may result in a significant reduction in seizure frequency according to parental reports. |
2018-10-22 |
2023-08-13 |
Not clear |
| Tamires Amabile Valim Brigante, Flavia R Abe, Antônio Waldo Zuardi, Jaime Eduardo Cecílio Hallak, José Alexandre S Crippa, Danielle P de Oliveir. Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos. Chemico-biological interactions. vol 291. 2018-07-27. PMID:29902416. |
cannabidiol (cbd) is a non-psychotomimetic compound of the cannabis sativa that has been used for the treatment of severe epilepsy as well as other diseases of nervous system. |
2018-07-27 |
2023-08-13 |
zebrafish |
| b' Dejana Ru\\xc5\\xbei\\xc4\\x87 Ze\\xc4\\x8devi\\xc4\\x87, Marko Foli\\xc4\\x87, Ziyad Tantoush, Milan Radovanovi\\xc4\\x87, Goran Babi\\xc4\\x87, Slobodan M Jankovi\\xc4\\x8. Investigational cannabinoids in seizure disorders, what have we learned thus far? Expert opinion on investigational drugs. vol 27. issue 6. 2018-07-20. PMID:29842819.' |
cannabinoids that are currently investigated with the intention of making them drugs for the treatment of epilepsy are cannabidiol, cannabidivarin, Δ9-tetrahydrocannabivarin, and Δ9-tetrahydrocannabinolic acid. |
2018-07-20 |
2023-08-13 |
Not clear |
| David E Mandelbau. Cannabidiol in patients with treatment-resistant epilepsy. The Lancet. Neurology. vol 15. issue 6. 2018-06-25. PMID:27302117. |
cannabidiol in patients with treatment-resistant epilepsy. |
2018-06-25 |
2023-08-13 |
Not clear |
| Prisca R Bauer, Josemir W Sande. Cannabidiol in patients with treatment-resistant epilepsy. The Lancet. Neurology. vol 15. issue 6. 2018-06-25. PMID:27302118. |
cannabidiol in patients with treatment-resistant epilepsy. |
2018-06-25 |
2023-08-13 |
Not clear |
| Orrin Devinsky, Eric Marsh, Daniel Friedma. Cannabidiol in patients with treatment-resistant epilepsy - Authors' reply. The Lancet. Neurology. vol 15. issue 6. 2018-06-25. PMID:27302119. |
cannabidiol in patients with treatment-resistant epilepsy - authors' reply. |
2018-06-25 |
2023-08-13 |
Not clear |
| Joshua S Kaplan, Nephi Stella, William A Catterall, Ruth E Westenbroe. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proceedings of the National Academy of Sciences of the United States of America. vol 114. issue 42. 2018-06-18. PMID:28973916. |
here we show that cannabidiol (cbd) effectively reduced seizures and autistic-like social deficits in a well-validated mouse genetic model of dravet syndrome (ds), a severe childhood epilepsy disorder caused by loss-of-function mutations in the brain voltage-gated sodium channel na |
2018-06-18 |
2023-08-13 |
mouse |
| G Pesantez-Rios, L Armijos-Acurio, R Jimbo-Sotomayor, S I Pascual-Pascual, G Pesantez-Cuest. [Cannabidiol: its use in refractory epilepsies]. Revista de neurologia. vol 65. issue 4. 2018-06-15. PMID:28726233. |
[cannabidiol: its use in refractory epilepsies]. |
2018-06-15 |
2023-08-13 |
Not clear |
| Elisa J Sob. Parent use of cannabis for intractable pediatric epilepsy: Everyday empiricism and the boundaries of scientific medicine. Social science & medicine (1982). vol 190. 2018-06-11. PMID:28865255. |
parent use of cannabis for intractable pediatric epilepsy: everyday empiricism and the boundaries of scientific medicine. |
2018-06-11 |
2023-08-13 |
Not clear |